Extended Data Fig. 7: ctDNA-based MRD testing is Predictive of Response to ACT in Oligometastatic stage IV ctDNA-positive patients who did not receive neoadjuvant chemotherapy.
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Kaplan-Meier estimates for disease-free survival stratified by observation (red) and adjuvant chemotherapy (blue) in oligometastatic stage IV patients with A. ctDNA positive patients who received neoadjuvant therapy; HR was adjusted for gender. B. ctDNA-positive patients who did not receive neoadjuvant chemotherapy; HR was adjusted for gender and performance status. A landmark analysis at 8 weeks was implemented to address the immortal time bias, whereby DFS was measured starting from day 60. HR and 95% CI were calculated by the Cox proportional hazard model. P-value was calculated using the two-sided log-rank test.
